Clinical Trial Update: Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update on Y-NM600 for patients with metastatic cancer receiving anti-PD-1 or anti-PD-L1 therapy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Y-NM600

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Metastatic Cancer | Phase 1 | Status: RECRUITING